Skip to main content
. 2016 Apr 30;25(11):2220–2233. doi: 10.1093/hmg/ddw090

Figure 3.

Figure 3.

Pharmacological inhibition of Tgf-β signaling improves left-ventricular function. (A) Schematic representation of the treatment protocol of LmnaH222P/H222P mice with SB-431542. (B) Representative immunoblots using antibodies against p-smad2/3 and total smad2/3 to probe proteins extracted from hearts from LmnaH222P/H222P mice (Lmna H222P) treated with placebo or SB-431542. Each lane contains protein extracts from a different mouse. (C) Mason trichrome staining of cross sections of hearts from LmnaH222P/H222P mice (Lmna H222P) treated with placebo or SB-431542. Scale bar: 50 μm. Bar diagrams indicate the expression of Col1a1 and Col1a2 from LmnaH222P/H222P mice (Lmna H222P) treated with placebo (n = 3) or SB-431542 (n = 5). *P < 0.05. (D) Graph showing mean left ventricle end-diastolic diameter (LVEDD), mean left ventricle end-systolic diameter (LVESD) and fraction shortening (FS) in 20-week-old male LmnaH222P/H222P mice (Lmna H222P) treated with placebo (n = 15) or SB-431542 (n = 9). Values for each individual mouse receiving placebo or SB-431542 as well as standard errors of means (bars) are shown. *P < 0.05, **P < 0.01. (E) Relative expression of mRNAs from genes encoding myosin light chain (Myl4), atrial natriuretic peptide A (NppA) and brain natriuretic peptide B (NppB) in LmnaH222P/H222P mice (Lmna H222P) treated with placebo (n = 3) or SB-431542 (n = 5). Values shown are means ± standard errors. **P < 0.01.